Key result
In patients with acute myocardial infarction, low-dose subcutaneous heparin for 30 days altered blood rheologic factors compared to conventional therapy, with no bleeding events.
Why the study?
Does subcutaneous heparin at low doses improve blood rheologic factors in patients with acute myocardial infarction?
Population
529 patients with acute myocardial infarction
Comparison
Subcutaneous heparin at low doses for 30 days vs Conventional therapy without antithrombotic drugs
Design
Cohort
Follow-up
30 days
Authors
Loading...
Low-dose heparin alters rheologic factors without bleeding in AMI; hypothesis-generating and requires RCTs before any practice change.
Cohort (n=529)
Does subcutaneous heparin at low doses improve blood rheologic factors in patients with acute myocardial infarction?
Low-dose subcutaneous heparin for 30 days in acute myocardial infarction improves blood rheologic factors without causing bleeding.
Ruggiero et al. (1987) conducted a cohort in Acute myocardial infarction (n=529). Subcutaneous heparin vs. Conventional therapy without antithrombotic drugs was evaluated on Blood rheologic factors (thrombo-elastography, platelet adhesiveness, total blood viscosity, and number of platelets). In patients with acute myocardial infarction, low-dose subcutaneous heparin for 30 days altered blood rheologic factors compared to conventional therapy, with no bleeding events.
Synapse has enriched one closely related paper. Consider it for comparative context: